Street View: AbbVie's strong drug pipeline sets it up well for long‑term growth

AbbVie ABBV.N forecast 2026 profit above Wall Street expectations on Wednesday after a Q4 beat driven by stronger‑than‑expected sales of its older immunology drug Humira

Median PT of 31 brokerages covering the stock is $245 - data compiled by LSEG

BUILT FOR THE LONG HAUL

J.P. Morgan ("overweight") believes co is delivering strong growth, faces minimal patent‑expiration risk over the next decade, and has a solid pipeline and business‑development options to support its long‑term outlook

Piper Sandler ("overweight," PT: $289) says that co’s neuroscience unit could provide meaningful upside and that its oncology business is set up for stronger long‑term growth as its antibody‑drug conjugate pipeline develops

Morgan Stanley ("overweight," PT: $270) expects co to post steady growth ahead and notes that progress in diversifying the pipeline will matter more as the market looks beyond the next decade

Morningstar (fair value: $184) says new drugs like Parkinson's therapy Vyalev are building on the continued growth of key immunology drugs Skyrizi and Rinvoq, further cementing the firm's sustainable growth